Home » Stocks » PROG

Progenity, Inc. (PROG)

Stock Price: $2.00 USD -0.10 (-4.76%)
Updated Aug 3, 2021 12:43 PM EDT - Market open
Market Cap 174.23M
Revenue (ttm) 82.01M
Net Income (ttm) -207.91M
Shares Out 57.49M
EPS (ttm) -5.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day August 3
Last Price $2.00
Previous Close $2.10
Change ($) -0.10
Change (%) -4.76%
Day's Open 2.05
Day's Range 1.97 - 2.06
Day's Volume 801,269
52-Week Range 1.97 - 10.27

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The company's Preecludia™ test performed strongly in a broad, intended-use population The company's Preecludia™ test performed strongly in a broad, intended-use population

5 days ago - GlobeNewsWire

SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced the appointment of Surbhi Sarna to its board of directors effective July 1, 20...

1 month ago - GlobeNewsWire

With July only a week away, which penny stocks are investors watching right now? The post Hot Penny Stocks to Buy in 2021?

Other stocks mentioned: ABEV, ENG, IVR, KIQ, OCGN, UEC
1 month ago - PennyStocks

SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the formation of its Inflammatory Bowel Disease Clinical Advisory Board....

1 month ago - GlobeNewsWire

Investors need to pay close attention to Progenity (PROG) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that Harry Stylli, PhD, CEO, chairman of the board, and co-founder of Pr...

1 month ago - GlobeNewsWire

Looking for penny stocks under $5? Check these 3 out The post Hot Penny Stocks to Buy Under $5?

Other stocks mentioned: GBS, RIG
1 month ago - PennyStocks

Women's health diagnostic firm, Progenity Inc (NASDAQ: PROG), will close its genetics laboratory as part of a strategic transformation that emphasizes its drug delivery technologies and therapeutics. Cl...

2 months ago - Benzinga

Progenity Inc (NASDAQ: PROG) has announced results from a preclinical study evaluating the delivery of PGN-001 (adalimumab liquid formulation) drug substance directly to the colon in an animal model of ...

2 months ago - Benzinga

Preclinical study shows therapeutic effect of locally delivered PGN-001 (adalimumab) drug substance Preclinical study shows therapeutic effect of locally delivered PGN-001 (adalimumab) drug substance

2 months ago - GlobeNewsWire

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the appointment of Sean Lavin, M.D. as Vice President, Business Developme...

2 months ago - GlobeNewsWire

Two Abstracts Support Company's Targeted Therapeutics Program including the Drug Delivery System Two Abstracts Support Company's Targeted Therapeutics Program including the Drug Delivery System

2 months ago - GlobeNewsWire

Provides educational resources for both patients and healthcare providers Provides educational resources for both patients and healthcare providers

2 months ago - GlobeNewsWire

Reports revenues of $24.5 million in the first quarter of 2021, up 72% from prior quarter

2 months ago - GlobeNewsWire

Studies show location accuracy and tolerability of the novel oral Drug Delivery System (DDS) and point to a materially enhanced therapeutic/safety index for PGN-600 Studies show location accuracy and to...

2 months ago - GlobeNewsWire

SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products,...

2 months ago - GlobeNewsWire

SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing produc...

2 months ago - GlobeNewsWire

Pre-validation study demonstrates commercial laboratory systems readiness; data show strong performance consistent with verification study Pre-validation study demonstrates commercial laboratory systems...

2 months ago - GlobeNewsWire

Progenity survey shows more women know their baby's “fruit size” than the key indicator of a common pregnancy complication

2 months ago - GlobeNewsWire

Data demonstrate strong sensitivity and negative predictive value (NPV) Data demonstrate strong sensitivity and negative predictive value (NPV)

3 months ago - GlobeNewsWire

SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing prod...

3 months ago - GlobeNewsWire

SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing product...

3 months ago - GlobeNewsWire

SAN DIEGO, April 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing product...

3 months ago - GlobeNewsWire

SAN DIEGO, March 27, 2021 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of Progenity, Inc. (NASDAQ: PROG) against certain of its officers and directors.  In June 2020, ...

4 months ago - PRNewsWire

Reports approximately 82,000 tests in the fourth quarter of 2020

4 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Silk Road" or the "Company") (NASDAQ: PROG). Such investors are ...

4 months ago - Newsfile Corp

SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing prod...

4 months ago - GlobeNewsWire

NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc.  ("Silk Road" or the "Company") (NASDAQ: PROG).  Such investors are advised to co...

4 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Silk Road" or the "Company") (NASDAQ: PROG). Such investors are a...

4 months ago - Newsfile Corp

NEW YORK, March 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Silk Road" or the "Company") (NASDAQ: PROG). Such investors are advised to conta...

5 months ago - PRNewsWire

SAN DIEGO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular...

5 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. (NASDAQ: PROG) ("Silk Road" or the "Company"). Such investors a...

5 months ago - Newsfile Corp

SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products...

5 months ago - GlobeNewsWire

Progenity applauds focus on preeclampsia biomarkers as it prepares for the launch of the Preecludia™ test Progenity applauds focus on preeclampsia biomarkers as it prepares for the launch of the Preeclu...

5 months ago - GlobeNewsWire

SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing produ...

5 months ago - GlobeNewsWire

Progenity's (NASDAQ:PROG) stock has been falling Monday, down 6.19% to a price of $5.9. Monday the stock has been traded at a volume of 209.31 thousand, about 29.44% of its recent 30-day volume average ...

5 months ago - Benzinga

The company celebrates its ten-year anniversary and looks toward future innovations The company celebrates its ten-year anniversary and looks toward future innovations

6 months ago - GlobeNewsWire

Total 2021 revenue expected to grow by up to 30% 1 , reaching a range of $130 to $145 million

6 months ago - GlobeNewsWire

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing produ...

6 months ago - GlobeNewsWire

Initial public offerings (IPOs) have been a hot topic of late, with big names like Airbnb and DoorDash having some of the biggest showings this year.

Other stocks mentioned: ANPC, CSPR, DNK, GRIL, LIZI, VEL
7 months ago - 24/7 Wall Street

SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing produ...

7 months ago - GlobeNewsWire

Adam Johnson of BullseyeBrief.com presented Tuesday at the Benzinga Global Small Cap Conference, discussing his fund of small-cap stock picks on Bullseye Brief, where subscribers can track his trades an...

Other stocks mentioned: KOP, REAL
7 months ago - Benzinga

SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing produ...

7 months ago - GlobeNewsWire

SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular...

7 months ago - GlobeNewsWire

SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced the pricing of its offering of $75.0 million aggregate principal amount of 7.25% convertible senior notes due ...

8 months ago - GlobeNewsWire

SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular...

8 months ago - GlobeNewsWire

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced its intention to offer, subject to market and other conditions, $75 million aggregate principal amount of conv...

8 months ago - GlobeNewsWire

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular...

8 months ago - GlobeNewsWire

High sensitivity and high negative predictive value (NPV) observed for ruling out the risk of preeclampsia High sensitivity and high negative predictive value (NPV) observed for ruling out the risk of p...

8 months ago - GlobeNewsWire

SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing produ...

8 months ago - GlobeNewsWire

About PROG

Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated wi... [Read more...]

Industry
Biotechnology
IPO Date
Jun 19, 2020
CEO
Harry Stylli
Employees
637
Stock Exchange
NASDAQ
Ticker Symbol
PROG
Full Company Profile

Financial Performance

In 2020, Progenity's revenue was $74.31 million, a decrease of -48.39% compared to the previous year's $143.99 million. Losses were -$192.53 million, 30.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Progenity stock is "Strong Buy." The 12-month stock price forecast is 4.75, which is an increase of 137.50% from the latest price.

Price Target
$4.75
(137.50% upside)
Analyst Consensus: Strong Buy